インダンタドール (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "インダンタドール" in Japanese language version.

refsWebsite

Global rank Japanese rank

4^th place

24^th place

2^nd place

6^th place

low place

low place

610^th place

915^th place

low place

low place

1aspetjournals.org

6,663^rd place

low place

aspetjournals.org

jpet.aspetjournals.org

Villetti G, Bergamaschi M, Bassani F, et al. (August 2003). “Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain”. The Journal of Pharmacology and Experimental Therapeutics 306 (2): 804-14. doi:10.1124/jpet.103.050039. PMID 12750440.

doi.org

Villetti G, Bregola G, Bassani F, et al. (June 2001). “Preclinical evaluation of CHF3381 as a novel antiepileptic agent”. Neuropharmacology 40 (7): 866-78. doi:10.1016/S0028-3908(01)00026-0. PMID 11378157.
Gandolfi O, Bonfante V, Voltattorni M, et al. (September 2001). “Anticonvulsant preclinical profile of CHF 3381: dopaminergic and glutamatergic mechanisms”. Pharmacology, Biochemistry, and Behavior 70 (1): 157-66. doi:10.1016/S0091-3057(01)00591-3. PMID 11566153.
Zucchini S, Buzzi A, Bergamaschi M, Pietra C, Villetti G, Simonato M (November 2002). “Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist”. Neuroreport 13 (16): 2071-4. doi:10.1097/00001756-200211150-00016. PMID 12438928.
Villetti G, Bergamaschi M, Bassani F, et al. (August 2003). “Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain”. The Journal of Pharmacology and Experimental Therapeutics 306 (2): 804-14. doi:10.1124/jpet.103.050039. PMID 12750440.
Mathiesen O, Imbimbo BP, Hilsted KL, Fabbri L, Dahl JB (August 2006). “CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model”. The Journal of Pain 7 (8): 565-74. doi:10.1016/j.jpain.2006.02.004. PMID 16885013.
Barbieri M, Bregola G, Buzzi A, et al. (August 2003). “Mechanisms of action of CHF3381 in the forebrain”. British Journal of Pharmacology 139 (7): 1333-41. doi:10.1038/sj.bjp.0705381. PMC 1573965. PMID 12890713.

elsevier.com

linkinghub.elsevier.com

Villetti G, Bregola G, Bassani F, et al. (June 2001). “Preclinical evaluation of CHF3381 as a novel antiepileptic agent”. Neuropharmacology 40 (7): 866-78. doi:10.1016/S0028-3908(01)00026-0. PMID 11378157.
Gandolfi O, Bonfante V, Voltattorni M, et al. (September 2001). “Anticonvulsant preclinical profile of CHF 3381: dopaminergic and glutamatergic mechanisms”. Pharmacology, Biochemistry, and Behavior 70 (1): 157-66. doi:10.1016/S0091-3057(01)00591-3. PMID 11566153.
Mathiesen O, Imbimbo BP, Hilsted KL, Fabbri L, Dahl JB (August 2006). “CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model”. The Journal of Pain 7 (8): 565-74. doi:10.1016/j.jpain.2006.02.004. PMID 16885013.

nih.gov

pubmed.ncbi.nlm.nih.gov

Villetti G, Bregola G, Bassani F, et al. (June 2001). “Preclinical evaluation of CHF3381 as a novel antiepileptic agent”. Neuropharmacology 40 (7): 866-78. doi:10.1016/S0028-3908(01)00026-0. PMID 11378157.
Gandolfi O, Bonfante V, Voltattorni M, et al. (September 2001). “Anticonvulsant preclinical profile of CHF 3381: dopaminergic and glutamatergic mechanisms”. Pharmacology, Biochemistry, and Behavior 70 (1): 157-66. doi:10.1016/S0091-3057(01)00591-3. PMID 11566153.
Zucchini S, Buzzi A, Bergamaschi M, Pietra C, Villetti G, Simonato M (November 2002). “Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist”. Neuroreport 13 (16): 2071-4. doi:10.1097/00001756-200211150-00016. PMID 12438928.
Villetti G, Bergamaschi M, Bassani F, et al. (August 2003). “Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain”. The Journal of Pharmacology and Experimental Therapeutics 306 (2): 804-14. doi:10.1124/jpet.103.050039. PMID 12750440.
“CHF 3381”. Drugs in R&D 5 (1): 28-30. (2004). PMID 14725488.
Mattia C, Coluzzi F (September 2007). “Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain”. IDrugs : the Investigational Drugs Journal 10 (9): 636-44. PMID 17786847.
Mathiesen O, Imbimbo BP, Hilsted KL, Fabbri L, Dahl JB (August 2006). “CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model”. The Journal of Pain 7 (8): 565-74. doi:10.1016/j.jpain.2006.02.004. PMID 16885013.
Barbieri M, Bregola G, Buzzi A, et al. (August 2003). “Mechanisms of action of CHF3381 in the forebrain”. British Journal of Pharmacology 139 (7): 1333-41. doi:10.1038/sj.bjp.0705381. PMC 1573965. PMID 12890713.

ncbi.nlm.nih.gov

Barbieri M, Bregola G, Buzzi A, et al. (August 2003). “Mechanisms of action of CHF3381 in the forebrain”. British Journal of Pharmacology 139 (7): 1333-41. doi:10.1038/sj.bjp.0705381. PMC 1573965. PMID 12890713.

vernalis.com

“IN-STEP Phase IIb study results”. 2010年4月12日閲覧。
“Vernalis initiates Pilot Study of V3381 in patients with chronic cough”. 2010年4月12日閲覧。
“V3381CC”. 2010年4月12日閲覧。
“Vernalis completes recruitment in V3381 Phase II IN-STEP study for neuropathic pain”. 2010年4月12日閲覧。

wkhealth.com

meta.wkhealth.com

Zucchini S, Buzzi A, Bergamaschi M, Pietra C, Villetti G, Simonato M (November 2002). “Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist”. Neuroreport 13 (16): 2071-4. doi:10.1097/00001756-200211150-00016. PMID 12438928.